Literature DB >> 28581884

Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer.

Rodrigo Goncalves1, Tomás Reinert1, Matthew J Ellis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28581884     DOI： 10.1200/JCO.2017.73.0424

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.

Authors:  Svasti Haricharan; Nindo Punturi; Purba Singh; Kimberly R Holloway; Meenakshi Anurag; Jacob Schmelz; Cheryl Schmidt; Jonathan T Lei; Vera Suman; Kelly Hunt; John A Olson; Jeremy Hoog; Shunqiang Li; Shixia Huang; Dean P Edwards; Shyam M Kavuri; Matthew N Bainbridge; Cynthia X Ma; Matthew J Ellis
Journal:  Cancer Discov       Date:  2017-08-11       Impact factor: 39.397

Review 2.  Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer.

Authors:  Tomás Reinert; Rodrigo Gonçalves; Matthew J Ellis
Journal:  Curr Treat Options Oncol       Date:  2018-04-16

Review 3.  The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.

Authors:  Ailin Zhang; Xiaojing Wang; Chuifeng Fan; Xiaoyun Mao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-03       Impact factor: 5.555
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.